Zhang X demonstrated for the first time that CD103+CD8+ Tregs could significantly reduce Th17-mediated corneal barrier dysfunction in in a murine model of SS by inhibiting DCs activation (13). This evidence concerns the gene CD8A and synovial sarcoma.